Breaking News Instant updates and real-time market news.

SPRO

Spero Therapeutics

$11.29

-0.46 (-3.91%)

16:40
08/09/18
08/09
16:40
08/09/18
16:40

Spero Therapeutics reports Q2 EPS (69c), consensus (78c)

As of June 30, 2018, the Company's cash, cash equivalents and marketable securities totaled $66.6 million. In early July, Spero completed a follow-on offering in which it issued 3,780,000 shares of common stock at a price of $12.50 per share, and 2,220 shares of Series A Convertible Preferred Stock at a price of $12,500 per share, for net proceeds before expenses of $70.5 million after deducting underwriting discounts and commissions. Spero believes that its existing cash, cash equivalents and marketable securities, together with the proceeds from the follow-on offering and initial committed funding of $15.7 million under the BARDA award, will fund operations into the second half of 2020, including through top-line data readout of the planned pivotal Phase 3 clinical trial of SPR994. A portion of the funding from our BARDA award is scheduled to support the development of SPR994 beyond 2020, provided we achieve the specified milestones and BARDA exercises all of its options under the agreement.

SPRO Spero Therapeutics
$11.29

-0.46 (-3.91%)

02/08/18
CANT
02/08/18
INITIATION
Target $27
CANT
Overweight
Spero Therapeutics initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Louise Chen initiated Spero Therapeutics with an Overweight and $27 price target.
02/09/18
02/09/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Motorola Solutions (MSI) initiated with a Neutral at JPMorgan. 2. Spero Therapeutics (SPRO) initiated with an Overweight at Cantor Fitzgerald. 3. County Bancorp (ICBK) initiated with a Neutral at DA Davidson. 4. Diplomat Pharmacy (DPLO) initiated with a Buy at Lake Street. 5. Pulmatrix (PULM) initiated with a Buy at H.C. Wainwright. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
04/03/18
CANT
04/03/18
NO CHANGE
Target $27
CANT
Overweight
Spero Therapeutics should rally as pipeline advances, says Cantor Fitzgerald
Cantor Fitzgerald analyst Louise Chen reiterates an Overweight rating on Spero Therapeutics with a $27 price target following the company's "solid" Q4 results. The analyst expects upward earnings revisions and multiple expansion as the company advances its pipeline toward commercialization.
05/11/18
HCWC
05/11/18
INITIATION
Target $28
HCWC
Buy
Spero Therapeutics initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Ed Arce started Spero Therapeutics with a Buy rating and $28 price target. The company has a differentiated antibiotic pipeline addressing multi-drug resistant infections with multiple near-term catalysts, the analyst contends.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.